Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Next Previous
Trial Profile

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms DELIVER
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 08 Apr 2024 Results assessing the association between septal wall thickness (SWT) and posterior wall thickness (PWT), the primary outcome (CV death or worsening HF), and treatment with dapagliflozin presented at the 73rd Annual Scientific Session of the American College of Cardiology
  • 01 Dec 2023 Results of a patient level pooled analysis assessing efficacy of Dapagliflozin according to Heart Rate from two clinical trials: DAPA-HF and DELIVER trials published in the Circulation: Heart Failure
  • 13 Nov 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top